Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
1(11%)
Results Posted
0%(0 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
2
22%
Ph phase_2
7
78%

Phase Distribution

2

Early Stage

7

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
7(77.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(7)
Terminated(1)

Detailed Status

Completed7
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
87.5%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (22.2%)
Phase 27 (77.8%)

Trials by Status

terminated111%
completed778%
recruiting111%

Recent Activity

1 active trials
Showing 5 of 9
recruitingphase_2

AT1001 for the Treatment of Long COVID

NCT05747534
terminatedphase_2

AT1001 for the Treatment of COVID-19 Related MIS-C

NCT05022303
completedphase_2

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

NCT01396213
completedphase_2

Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease

NCT00492960
completedphase_2

Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease

NCT00620451
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05747534Phase 2

AT1001 for the Treatment of Long COVID

Recruiting
NCT05022303Phase 2

AT1001 for the Treatment of COVID-19 Related MIS-C

Terminated
NCT01396213Phase 2

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

Completed
NCT00492960Phase 2

Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease

Completed
NCT00620451Phase 2

Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease

Completed
NCT00889473Phase 2

Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease

Completed
NCT00362856Phase 2

Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects

Completed
NCT00386490Phase 1

Safety of Larazotide Acetate in Healthy Volunteers

Completed
NCT00386165Phase 1

Safety Study of Larazotide Acetate to Treat Celiac Disease.

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9